Teneobio, Inc.
https://www.teneobio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Teneobio, Inc.
ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma
Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.
Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
Gilead Wagers $275m On Pionyr’s Myeloid Tuners
Deal snapshot: Pionyr’s top two candidates are preclinical, but Gilead buys near 50% stake in the hope that myeloid tuners will work in combination with anti-PD-L1 agents in solid tumors.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- OMT Therapeutics Inc
- Recombinant Antibody Technology (RAT) Ltd.